Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00895830 · ClinicalTrials.gov registry record · Phase 2

Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)

A Phase 2 study of Postoperative Nausea and Vomiting, sponsored by Acacia Pharma.

Completed
Registry status
Phase 2
Development phase
257
Enrollment target
18
Study locations

NCT00895830 is a Phase 2 study of Postoperative Nausea and Vomiting that has completed, run by Acacia Pharma. The registered enrollment target is 257 participants, below the 442-participant average among 9 other Postoperative Nausea and Vomiting trials with a reported enrollment target (42% lower). The trial reports 18 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00895830, a Phase 2 study of Postoperative Nausea and Vomiting, has completed, sponsored by Acacia Pharma.

COMPLETED
Registry status
Phase 2
Development phase
257 participants
Enrollment target
18
Study locations

Study Summary

To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.

Conditions Studied

Postoperative Nausea and Vomiting

Interventions

  • DRUG Placebo
  • DRUG APD405

Study Locations (18)

Other

  • University Hospital - Besançon
  • Hôpital mère enfant - Bron
  • Hôpital Huriez - Lille
  • University Hospital - Nancy
  • Hôpital FOCH - Paris
  • University Hospital - Reims
  • Hautepierre Hospital - Strasbourg
  • Charité - Universitätsmedizin - Berlin
  • Universität Heidelberg - Heidelberg
  • University of Leipzig - Leipzig
  • Klinikum Ludwigshafen - Ludwigshafen
  • Philipps University - Marburg
  • University Hospitals of Würzburg - Würzburg
  • Geneva University Hospitals - Geneva
  • Centre Hospitalier Universitaire Vaudois - Lausanne

California

  • UCSF Medical Center at Mt Zion - San Francisco

North Carolina

  • Duke University Medical Center - Durham

Texas

  • Memorial Hermann-Memorial City Hospital - Houston

Trial Details

FieldValue
Enrollment Target 257 participants
Start Date 2009-05
Est. Completion 2009-11
Phase Phase 2

Sponsor

Acacia Pharma

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00895830

The ClinicalTrials.gov registry entry for NCT00895830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 442-participant average among 9 other Postoperative Nausea and Vomiting trials with a reported enrollment target (42% lower). The listed sponsor is Acacia Pharma, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postoperative Nausea and Vomiting appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00895830 reports 18 study locations spanning 4 distinct geographic areas - top geographies include Other, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00895830 about?

NCT00895830 is a clinical study titled "Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)". To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystec...

What is the current status of trial NCT00895830?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 257 participants. The study started on 2009-05. Estimated completion is 2009-11.

What conditions does trial NCT00895830 study?

This clinical trial studies the following conditions: Postoperative Nausea and Vomiting.

What interventions are being tested in trial NCT00895830?

The interventions under investigation include: Placebo (DRUG), APD405 (DRUG).

Who is sponsoring clinical trial NCT00895830?

This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00895830 being conducted?

This trial has 18 study locations across California, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Postoperative Nausea and Vomiting

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Postoperative Nausea and Vomiting

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.